/BWAY
BWAY Stock - BrainsWay Ltd.
Healthcare|Medical - DevicesNASDAQ
$17.11+5.68%
+$0.92 (+5.68%) • Dec 19
88
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.90
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+40.3%upside
Target: $24.01
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BWAY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$16.94 – $17.28
TARGET (TP)$24.00
STOP LOSS$15.74
RISK/REWARD1:5.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.27
52W High$18.18
52W Low$7.84
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $41.02M | $31.79M | $27.18M | $29.66M | $22.06M |
| Gross Profit | $30.58M | $23.48M | $20.05M | $23.06M | $17.00M |
| Gross Margin | 74.6% | 73.9% | 73.8% | 77.7% | 77.1% |
| Operating Income | $1.39M | $-4,959,000 | $-12,683,000 | $-4,999,000 | $-4,829,000 |
| Net Income | $2.92M | $-4,197,000 | $-13,349,000 | $-6,462,000 | $-5,385,000 |
| Net Margin | 7.1% | -13.2% | -49.1% | -21.8% | -24.4% |
| EPS | $0.17 | $-0.26 | $-0.86 | $-0.42 | $-0.48 |
Company Overview
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
0%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
0 Bullish0 Neutral/Bearish
Price Targets
No price targets available
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 16th 2023 | Raymond James | Downgrade | Market Perform | - |
Earnings History & Surprises
BWAYBeat Rate
47%
Last 17 quarters
Avg Surprise
+0.9%
EPS vs Estimate
Beats / Misses
8/9
Last 12 quarters
Latest EPS
$0.08
Q4 2025
EPS Surprise History
Q1 24
+100.0%
$0.01vs$0.01
Q2 24
+100.0%
$0.01vs$0.01
Q3 24
+100.0%
$0.04vs$0.02
Q4 24
+207.7%
$0.04vs$0.01
Q1 25
+60.0%
$0.08vs$0.05
Q2 25
+100.0%
$0.04vs$0.02
Q3 25
No data
Q4 25
-27.3%
$0.08vs$0.11
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 11, 2026 | — | — | — | — |
Q1 2026 | Mar 10, 2026 | $0.11 | — | — | — |
Q4 2025 | Nov 11, 2025 | $0.11 | $0.08 | -27.3% | ✗ MISS |
Q3 2025 | Sep 30, 2025 | — | $0.11 | — | — |
Q2 2025 | May 13, 2025 | $0.02 | $0.04 | +100.0% | ✓ BEAT |
Q1 2025 | Mar 11, 2025 | $0.05 | $0.08 | +60.0% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $0.01 | $0.04 | +207.7% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $0.02 | $0.04 | +100.0% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $0.01 | $0.01 | +100.0% | ✓ BEAT |
Q1 2024 | Mar 6, 2024 | $0.01 | $0.01 | +100.0% | ✓ BEAT |
Q4 2023 | Nov 15, 2023 | $-0.07 | $-0.01 | +85.7% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $-0.17 | $-0.10 | +41.2% | ✓ BEAT |
Q2 2023 | May 17, 2023 | $-0.12 | $-0.14 | -16.7% | ✗ MISS |
Q1 2023 | Mar 15, 2023 | $-0.12 | $-0.24 | -100.0% | ✗ MISS |
Q4 2022 | Nov 16, 2022 | $-0.07 | $-0.30 | -328.6% | ✗ MISS |
Q3 2022 | Aug 10, 2022 | $-0.08 | $-0.14 | -75.0% | ✗ MISS |
Q2 2022 | May 11, 2022 | $-0.09 | $-0.12 | -33.3% | ✗ MISS |
Q1 2022 | Mar 9, 2022 | $-0.05 | $-0.08 | -60.0% | ✗ MISS |
Q4 2021 | Nov 17, 2021 | $-0.06 | $-0.10 | -66.7% | ✗ MISS |
Q3 2021 | Aug 11, 2021 | $-0.07 | $-0.12 | -71.4% | ✗ MISS |
Latest News
HC Wainwright & Co. Maintains Buy on BrainsWay, Raises Price Target to $24
📈 PositiveBenzinga•Dec 8, 2025, 12:37 PM
BrainsWay Commences Multicenter Clinical Study Evaluating Deep TMS 360 System In Patients With Alcohol Use Disorder
➖ NeutralBenzinga•Nov 17, 2025, 12:38 PM
HC Wainwright & Co. Maintains Buy on BrainsWay, Raises Price Target to $18
📈 PositiveBenzinga•Nov 13, 2025, 06:01 PM
The FDA Has Granted Label Expansion For Brainsway's Deep Transcranial Magnetic Stimulation System, Making The Treatment Available As An Adjunct Therapy For Adolescents Aged 15 To 21 Years Suffering From Major Depressive Disorder
📈 PositiveBenzinga•Nov 13, 2025, 11:06 AM
Northland Capital Markets Maintains Outperform on BrainsWay, Raises Price Target to $23
📈 PositiveBenzinga•Nov 12, 2025, 06:07 PM
BrainsWay Raises FY2025 Sales Guidance from $50.000M-$52.000M to $51.000M-$52.000M
📈 PositiveBenzinga•Nov 11, 2025, 12:31 PM
BrainsWay Q3 EPS $0.04 Misses $0.07 Estimate, Sales $13.512M Beat $13.041M Estimate
➖ NeutralBenzinga•Nov 11, 2025, 12:30 PM
BrainsWay Awarded $2.5M Grant From U.S. NIH To Support Clinical Trial Evaluating Deep Transcranial Magnetic Stimulation Protocol Through BrainsWay's Device For Alcohol Use Disorder Treatment
📈 PositiveBenzinga•Nov 4, 2025, 01:09 PM
BrainsWay Announces Strategic Investment In Heading Health, Commits Up To $4M To Expand Mental Health Clinic Network
📈 PositiveBenzinga•Oct 27, 2025, 11:46 AM
BrainsWay rises as FDA clears accelerated Deep TMS protocol
📈 PositiveSeeking Alpha•Sep 16, 2025, 05:41 PM
BrainsWay Announces FDA Granted Expansion Of Cleared Treatment Protocols For The Company's Deep TMS To Include Accelerated Protocol For Major Depressive Disorder
📈 PositiveBenzinga•Sep 16, 2025, 12:33 PM
HC Wainwright & Co. Reiterates Buy on BrainsWay, Maintains $17 Price Target
📈 PositiveBenzinga•Aug 25, 2025, 11:03 AM
BrainsWay Announces Strategic Investment In Neurolief Ahead Of FDA Approval And Commercial Launch Of Proliv Rx For Major Depressive Disorder
📈 PositiveBenzinga•Aug 21, 2025, 01:34 PM
BrainsWay Closes $5M Convertible Note Loan Investment In Neurolief
📈 PositiveBenzinga•Aug 21, 2025, 11:31 AM
BrainsWay Invests $2.3M In Axis Mental Health Clinics With Option For $1M More
📈 PositiveBenzinga•Aug 20, 2025, 11:38 AM
Frequently Asked Questions about BWAY
What is BWAY's current stock price?
BrainsWay Ltd. (BWAY) is currently trading at $17.11 per share. The stock has moved +5.68% today.
What is the analyst price target for BWAY?
The average analyst price target for BWAY is $24.00, based on 1 analyst.
What sector is BrainsWay Ltd. in?
BrainsWay Ltd. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the NASDAQ exchange.
What is BWAY's market cap?
BrainsWay Ltd. has a market capitalization of $0.33 billion, making it a small-cap company.
Does BWAY pay dividends?
No, BrainsWay Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCERS
Cerus Corporation
$2.09
Mkt Cap: $0.4B
CVRX
CVRx, Inc.
$8.03
Mkt Cap: $0.2B
DCTH
Delcath Systems, Inc.
$10.06
Mkt Cap: $0.3B
MASS
908 Devices Inc.
$5.84
Mkt Cap: $0.2B
NPCE
NeuroPace, Inc.
$16.59
Mkt Cap: $0.6B
RXST
RxSight, Inc.
$12.03
Mkt Cap: $0.5B
SENS
Senseonics Holdings, Inc.
$6.15
Mkt Cap: $0.3B
SGHT
Sight Sciences, Inc.
$8.45
Mkt Cap: $0.4B
TCMD
Tactile Systems Technology, Inc.
$28.92
Mkt Cap: $0.6B
VMD
Viemed Healthcare, Inc.
$7.42
Mkt Cap: $0.3B
Explore stocks similar to BWAY for comparison